CAR - T Cell therapy, CAR T Therapy, CAR T-Cell, chimeric agent
A Deep Dive into CAR T Cell Therapy: How Does It Work?
Discover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about this miraculous therapy and how ..
CAR - T Cell therapy, CAR T-Cell, Chimeric Agent Receptor, Korea, Seoul, South Korea
Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy
May 2023: Chimeric antigen receptor (CAR) T-cell therapy is an innovative development in the field of individualized cancer therapy. The patient's own T-cells are genetically modified during the manufacturing process to express a..
Biotechnology, CAR - T Cell therapy, CAR T-Cell, CAR therapy, China, fund raise, Oricell Therapeutics
Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States
23rd March 2023: The preclinical and early-stage cancer cell therapies being developed by Shanghai biotech Oricell have received an additional $45 million in funding, the company announced on Tuesday. Following a showing at AS..
Australia, CAR - T Cell therapy, CAR T Therapy, Cartherics
Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy
March 2023: Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development programme agreement (CDPA) to develop CTH-002 for the treatment of ovarian cancer. The cli..
CAR - T Cell therapy, CAR T-Cell, Emily Littlejohn, Immunology, lupus renaissance
New CAR T-Cell therapy drug in lupus renaissance
Feb 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a "renaissance" for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy ..
anti-BCMA, CAR - T Cell therapy, CT103A, FDA, IASO Biotherapeutics, Innovent Biologics, orphan drug designation
CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug design..
CAR - T Cell therapy, China, IASO Biotherapeutics, multiple myeloma
CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval
Feb 2023: IASO Biotherapeutics' investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track and regenerative medicine advanced therapy designations from the U.S. Food and..
CAR - T Cell therapy, Seoul, South Korea
AMC opens up CAR T-Cell therapy center in Seoul
Jan 2023: The Asan Medical Center (AMC) opened the first CAR-T cell treatment facility in the country after the government approved health insurance benefits for Kymriah's CAR-T cell therapy.AMC announced on Tuesday that its canc..
Blood Test, CAR - T Cell therapy, JAMA Oncology, neurofilament light chain, Neurotoxic Complications, Washington University
CAR T-Cell therapy complications can be predicted by a simple blood test
Sept 2022: The treatment of various tumours has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. In order to target and combat specific forms of leukaemia and lymphoma, the treatment employs genetic..
CAR - T Cell therapy, CARsgen Therapeutics Co, Daiichi Sankyo Company, DLBCL, Emergen Research, Limited, Novartis AG
CAR T-Cell therapy market will grow at phenomenal rate in next 8 years
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion in 2021 and is expected to register a revenue CAGR of 24.9 percent ..